Integrative analysis of ASXL family genes reveals ASXL2 as an immunoregulatory molecule in head and neck squamous cell carcinoma

• Published in: Scientific reports 2024-12, Vol.14 (1), p.31368-14, Article 31368
• Main Authors: Liu, Qian, Zhu, Wenhao, Tang, Chenpeng, Liu, Wenbin, Luo, Xiangjian
• Format: Article
• Language: English
• Subjects: 631/67/1536; 692/308/53; ASXL2; Biomarkers; Biomarkers, Tumor - genetics; Cell activation; Cell survival; Female; Gene Expression Regulation, Neoplastic; Head and neck carcinoma; Head and Neck Neoplasms - genetics; Head and Neck Neoplasms - immunology; Head and Neck Neoplasms - pathology; Head and neck squamous cell carcinoma; Humanities and Social Sciences; Humans; Immunoregulation; Immunotherapy; Interferon-gamma - genetics; Interferon-gamma - metabolism; Lymphocytes; Lymphocytes T; Male; Malignancy; Medical prognosis; Metastases; multidisciplinary; Prognosis; Repressor Proteins - genetics; Repressor Proteins - metabolism; Science; Science (multidisciplinary); Signal Transduction; Squamous cell carcinoma; Squamous Cell Carcinoma of Head and Neck - genetics; Squamous Cell Carcinoma of Head and Neck - immunology; T-Lymphocytes - immunology; T-Lymphocytes - metabolism; Tumor microenvironment; Tumor Microenvironment - genetics; Tumor Microenvironment - immunology; γ-Interferon
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-024-82815-8

Despite the progress in conventional treatments for head and neck squamous cell carcinoma (HNSCC), the 5-year survival rate remains below 70%. Enhancing immunotherapy outcomes through personalized treatment strategies, particularly by identifying immune-related biomarkers, is critical. The ASXL family are associated with malignancies, but their relationship with HNSCC has not been elucidated. In this study, we found that high expression of ASXL2 is associated with better prognosis in HNSCC patients. Analysis revealed a significant positive correlation between ASXL2 and immune infiltration. Functional analysis suggests that ASXL2 co-expressed genes in HNSCC patients are enriched in the JAK-STAT signaling pathway, and patients with high expression show an even greater enrichment in T cell and B cell receptor signaling pathways. Utilizing the NPC single-cell dataset, ASXL2’s widespread expression in the tumor microenvironment was confirmed, and its co-expressed genes were found to be highly associated with immune cell function. Experimental validation showed a correlation between ASXL2 expression and T cell secretion of interferon-γ (IFNγ), confirming that high ASXL2 expression facilitates T cell activation. Overall, our findings underscore the important role of ASXL2 in immune activation, suggesting its potential as a promising biomarker for tailoring immunotherapy strategies in HNSCC patients.